Pfizer struck a broad multi-drug R&D collaboration with Innovent Biologics covering up to 12 oncology programs, including antibody-drug conjugates and multispecific antibodies. Pfizer will take over global development after Phase 1 for several assets, with Innovent leading early development and handling discovery work for the portfolio. The deal includes $650 million up front and up to $9.85 billion in downstream milestones plus royalties. The transaction positions China-based discovery and early clinical execution as a core input into global portfolios, aligning with a broader shift toward cross-border, multi-asset licensing rather than single-product deals. For competitors and partners, the agreement raises the bar for differentiated ADC/multispecific pipelines while intensifying global race dynamics around early-stage throughput.